Atomic Laboratory is a Boston-based research organization advancing human immunology through clinical research, artificial intelligence, and advanced “omics” technologies. Founded in 2019, it designs and conducts clinical studies that collect detailed data across diverse biomarkers and patient groups, supporting rigorous analysis of immune responses. The laboratory applies machine learning and computational methods to complex biological datasets to identify biomarkers, explore disease mechanisms, and inform predictive and personalized therapeutic strategies.

Its research includes the FluPRINT Study, which examined systems-level immune responses to a live attenuated influenza vaccine, as well as studies investigating vaccine effectiveness and the duration of protection following previous coronavirus infection. Atomic Laboratory also reports expanding its research facilities, launching new clinical trials, and establishing an artificial intelligence data center.

Rather than offering consumer products, the organization provides scientific research and collaboration opportunities in human and systems immunology. Its work brings together laboratory experimentation, clinical study design, data science, and computational biology, with a focus on pathogens, vaccines, and immune-system interactions.